We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?
Biotech leader Gilead Sciences (GILD - Free Report) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.
Thanks to its durable drug pipeline for HIV and liver disease, Gilead's stock has been on a captivating ascension in the last two years, producing gains of +100% and hitting an all-time high of $157 a share in today’s trading session.
Gilead’s Favorable Q4 results
Gilead posted Q4 sales of $7.92 billion, a 5% increase from $7.56 billion in the comparative quarter and topping estimates of $7.57 billion. HIV franchise sales grew 6%, driven by strong demand for prevention and treatment products like Biktarvy and Descovy, with liver disease revenue rising 17%, led by Livdelzi.
Net income for the quarter came in at $2.2 billion or adjusted EPS of $1.86, edging expectations of $1.83 despite a decline from $1.90 per share a year ago.
Image Source: Zacks Investment Research
Full Year Results & Guidance
The spark behind Gilead’s post-earnings rally was that FY25 EPS spiked 76% to $8.15 compared to $4.62 per share in 2024. Furthermore, annual sales increased over 2% to $29.44 billion.
Offering full-year guidance for FY26, Gilead expects annual sales in a range of $29.6-$30 billion, which was slightly beneath Wall Street’s estimates of $30.04 billion or 2% growth. However, the top end of Gilead’s FY26 EPS Guidance ($8.45-$8.85) came in above the street’s expectations of $8.61 or 5% growth.
GILD is a Top Value Stock
Despite such an extensive rally, Gilead’s valuation may still be attracting investors at 17X forward earnings. Trading at a nice P/E discount to the benchmark S&P 500, this is also nicely beneath its Zacks Medical-Biomedical and Genetics Industry average of 19X forward earnings.
Image Source: Zacks Investment Research
The pharmaceutical giant also offers a 2.15% annual dividend yield as opposed to the S&P 500’s 1.07% average, while many of its industry peers don’t offer a payout.
Image Source: Zacks Investment Research
Gilead’s Intriguing ROIC
What may be most compelling to investors is that Gilead has shown a nice ability to turn invested capital into profits, one of the clearest indicators of long-term shareholder value.
With the admirable level being 20% or higher, Gilead’s return on invested capital (ROIC) is currently at 24%. It’s noteworthy that many other biopharmaceutical companies have an ROIC percentage closer to the mid-teens or single digits because of the immense R&D investment that is required.
Image Source: Zacks Investment Research
Bottom Line
Following favorable Q4 results, Gilead Sciences' stock currently lands a Zacks Rank #3 (Hold). GILD is certainly an intriguing option for long-term investors looking for value and income in the portfolio. That said, the plausibility of higher highs for GILD will likely depend on what is hopefully a sharper uptick in FY26 EPS revisions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?
Biotech leader Gilead Sciences (GILD - Free Report) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.
Thanks to its durable drug pipeline for HIV and liver disease, Gilead's stock has been on a captivating ascension in the last two years, producing gains of +100% and hitting an all-time high of $157 a share in today’s trading session.
Gilead’s Favorable Q4 results
Gilead posted Q4 sales of $7.92 billion, a 5% increase from $7.56 billion in the comparative quarter and topping estimates of $7.57 billion. HIV franchise sales grew 6%, driven by strong demand for prevention and treatment products like Biktarvy and Descovy, with liver disease revenue rising 17%, led by Livdelzi.
Net income for the quarter came in at $2.2 billion or adjusted EPS of $1.86, edging expectations of $1.83 despite a decline from $1.90 per share a year ago.
Image Source: Zacks Investment Research
Full Year Results & Guidance
The spark behind Gilead’s post-earnings rally was that FY25 EPS spiked 76% to $8.15 compared to $4.62 per share in 2024. Furthermore, annual sales increased over 2% to $29.44 billion.
Offering full-year guidance for FY26, Gilead expects annual sales in a range of $29.6-$30 billion, which was slightly beneath Wall Street’s estimates of $30.04 billion or 2% growth. However, the top end of Gilead’s FY26 EPS Guidance ($8.45-$8.85) came in above the street’s expectations of $8.61 or 5% growth.
GILD is a Top Value Stock
Despite such an extensive rally, Gilead’s valuation may still be attracting investors at 17X forward earnings. Trading at a nice P/E discount to the benchmark S&P 500, this is also nicely beneath its Zacks Medical-Biomedical and Genetics Industry average of 19X forward earnings.
Image Source: Zacks Investment Research
The pharmaceutical giant also offers a 2.15% annual dividend yield as opposed to the S&P 500’s 1.07% average, while many of its industry peers don’t offer a payout.
Image Source: Zacks Investment Research
Gilead’s Intriguing ROIC
What may be most compelling to investors is that Gilead has shown a nice ability to turn invested capital into profits, one of the clearest indicators of long-term shareholder value.
With the admirable level being 20% or higher, Gilead’s return on invested capital (ROIC) is currently at 24%. It’s noteworthy that many other biopharmaceutical companies have an ROIC percentage closer to the mid-teens or single digits because of the immense R&D investment that is required.
Image Source: Zacks Investment Research
Bottom Line
Following favorable Q4 results, Gilead Sciences' stock currently lands a Zacks Rank #3 (Hold). GILD is certainly an intriguing option for long-term investors looking for value and income in the portfolio. That said, the plausibility of higher highs for GILD will likely depend on what is hopefully a sharper uptick in FY26 EPS revisions.